SUPPLEMENTARY DATA

Supplementary Table S1. Antibodies, Source, and working dilution

Antibody	Company	Catalogue Number	Dilution
4-HNE	Abcam	Ab464545	1:100
GPX	Santa Cruz Biotechnology	sc-22145	1:200
Nrf2	Santa Cruz Biotechnology	sc-722	1:200
Galectin 3	Biolegend	125402	1:100
Glucagon	Santa Cruz Biotechnology	sc-13091	1:300
Insulin	Dako	A0564	1:500

SUPPLEMENTARY DATA

Supplementary Table S2. Docking scores of ML127 and ML351 with the human proteome forwhich comprehensive structural data are available.
Download or view data at: https://iu.app.box.com/v/SupplTableS2

SUPPLEMENTARY DATA

Supplementary Table S3. Genes significantly altered (P<0.05, FDR<0.05) in comparison between islets treated with pro-inflammatory cytokines (PIC) and pro-inflammatory cytokines + ML353 (PIC+ML).

Download or view data at: https://iu.app.box.com/v/SupplTableS3

SUPPLEMENTARY DATA

Supplementary Figure S1. Transcriptome analysis of mouse islets treated with cytokines and ML351. Mouse islets were treated for 24 hrs with vehicle (NT), 10 μM of ML351 (ML351), cytokines (cyto), cytokines+10 μM of ML351(cyto+ML351). **(A),** Principal component analysis of RNA sequencing results. **(B and C),** Volcano plots of RNA sequencing analysis. Data are from N=3 biologic replicates.



SUPPLEMENTARY DATA

Supplementary Figure S2. Galectin 3 immunostaining of pancreas of CD1 and NOD mice.
Fixed pancreatic sections from CD1 and NOD mice treated with vehicle or 24 mg/kg ML351 were subjected to immunofluorescence staining. Shown are representative images (*left panel*) and galectin-3-positive cells as a percent of cellular infiltrate (*right panel*) from analysis of at least three animals pergroup. Galectin-3 (Gal-3, *magenta*), insulin (*green*), and DAPI (*blue*). Magnification *x200*, scale bar *100 μm*. **P* <0.05 compared to NOD-MO.